drugset / Trial / NCT05320640
Study of Chidamide, Decitabine and Immune Checkpoint Inhibitors in R/R NHL and Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This phase I/II trial aims to evaluate safety and efficacy of Chidamide, Decitabine and Immune checkpoint inhibitors in relapsed/refractory Non-Hodgkin Lymphoma and advanced solid tumors.
Timeline
- Start
- 2022-03-30
- Primary completion
- 2024-04-01
- Completion
- 2025-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Decitabine | Small molecule | 10 mg | — |
| Subject | Tucidinostat | Small molecule | 20 mg | Oral |